Moderna, Inc. (MRNA)
收市後：
| 前收市價 | 142.55 |
| 開市 | 139.65 |
| 買盤 | 147.74 x 400 |
| 賣出價 | 147.93 x 400 |
| 今日波幅 | 137.52 - 150.80 |
| 52 週波幅 | 62.55 - 170.47 |
| 成交量 | |
| 平均成交量 | 4,084,692 |
| 市值 | 56.651B |
| Beta 值 (5 年，每月) | 1.57 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -15.60 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 138.94 |
Insider MonkeyIs Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Moderna, Inc. (NASDAQ:MRNA) is the top gene therapy stock to invest in now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
BenzingaModerna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
Motley FoolIs Moderna Stock a Buy Now That It's a 2-Product Company?
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.
